"Focused ultrasound allows for triggered drug release specifically in the tumor, thus minimizing systemic exposure and associated toxic effects," says Prof Tyrone Porter, the principal investigator of a new study to treat neurofibromatosis type 2.
"Focused ultrasound allows for triggered drug release specifically in the tumor, thus minimizing systemic exposure and associated toxic effects," says Prof Tyrone Porter, the principal investigator of a new study to treat neurofibromatosis type 2.
